Legend Biotech Shares Rise After Swinging to 2Q Profit, Higher Revenue

Dow Jones

Aug 11

Shares of Legend Biotech rose after the biopharmaceutical company swung to a second quarter profit and posted higher revenue.

The stock was up 6.4% to $22.06 in late morning trading on Tuesday, and is now up 1.5% this year.

The company posted net income of $33.2 million, or 9 cents a share, compared with a loss of $125.4 million, or 34 cents a share, a year earlier.

Revenue rose to $387.5 million from $255.1 million, driven by sales of Carvykti, an immunotherapy used to treat cancer of the bone marrow, known as multiple myeloma. Analysts polled by FactSet expected $356 million.

Interim Chief Executive Alan Bash said Carvykti expanded globally during the quarter and commercial momentum of Carvykti provided the foundation to advance a diversified portfolio of cell therapies.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2658257911"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658257911\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658257911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658257911","market":"fut","top_or_hot":-1,"title":"Legend Biotech Shares Rise After Swinging to 2Q Profit, Higher Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Legend Biotech rose after the biopharmaceutical company swung to a second quarter profit and posted higher revenue. \n</p>\n<p>\n  The stock was up 6.4% to $22.06 in late morning trading on Tuesday, and is now up 1.5% this year. \n</p>\n<p>\n  The company posted net income of $33.2 million, or 9 cents a share, compared with a loss of $125.4 million, or 34 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose to $387.5 million from $255.1 million, driven by sales of Carvykti, an immunotherapy used to treat cancer of the bone marrow, known as multiple myeloma. Analysts polled by FactSet expected $356 million. \n</p>\n<p>\n  Interim Chief Executive Alan Bash said Carvykti expanded globally during the quarter and commercial momentum of Carvykti provided the foundation to advance a diversified portfolio of cell therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Shares Rise After Swinging to 2Q Profit, Higher Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Shares Rise After Swinging to 2Q Profit, Higher Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-11 23:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Legend Biotech rose after the biopharmaceutical company swung to a second quarter profit and posted higher revenue. \n</p>\n<p>\n  The stock was up 6.4% to $22.06 in late morning trading on Tuesday, and is now up 1.5% this year. \n</p>\n<p>\n  The company posted net income of $33.2 million, or 9 cents a share, compared with a loss of $125.4 million, or 34 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose to $387.5 million from $255.1 million, driven by sales of Carvykti, an immunotherapy used to treat cancer of the bone marrow, known as multiple myeloma. Analysts polled by FactSet expected $356 million. \n</p>\n<p>\n  Interim Chief Executive Alan Bash said Carvykti expanded globally during the quarter and commercial momentum of Carvykti provided the foundation to advance a diversified portfolio of cell therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2658257911","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658257911","pubTimestamp":1786462860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Legend Biotech rose after the biopharmaceutical company swung to a second quarter profit and posted higher revenue.The stock was up 6.4% to $22.06 in late morning trading on Tuesday, and is now up 1.5% this year.The company posted net income of $33.2 million, or 9 cents a share, compared with a loss of $125.4 million, or 34 cents a share, a year earlier.Revenue rose to $387.5 million from $255.1 million, driven by sales of Carvykti, an immunotherapy used to treat cancer of the bone marrow, known as multiple myeloma. Analysts polled by FactSet expected $356 million.Interim Chief Executive Alan Bash said Carvykti expanded globally during the quarter and commercial momentum of Carvykti provided the foundation to advance a diversified portfolio of cell therapies.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XBI":"SPDR S&P Biotech ETF","LEGN":"传奇生物"},"translate_title":"传奇生物股价在第二季度盈利和收入增加后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"LEGN":1.5},"content_text":"Shares of Legend Biotech rose after the biopharmaceutical company swung to a second quarter profit and posted higher revenue. \n\n\n  The stock was up 6.4% to $22.06 in late morning trading on Tuesday, and is now up 1.5% this year. \n\n\n  The company posted net income of $33.2 million, or 9 cents a share, compared with a loss of $125.4 million, or 34 cents a share, a year earlier. \n\n\n  Revenue rose to $387.5 million from $255.1 million, driven by sales of Carvykti, an immunotherapy used to treat cancer of the bone marrow, known as multiple myeloma. Analysts polled by FactSet expected $356 million. \n\n\n  Interim Chief Executive Alan Bash said Carvykti expanded globally during the quarter and commercial momentum of Carvykti provided the foundation to advance a diversified portfolio of cell therapies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}